November 28, 2018 / 6:39 PM / 14 days ago

BRIEF-FDA Says Granted Approval Of Truxima To Celltrion As First Biosimilar To Rituxan

Nov 28 (Reuters) - U.S. Food and Drug Administration:

* FDA APPROVES TRUXIMA, FIRST BIOSIMILAR FOR TREATMENT OF ADULT PATIENTS WITH NON-HODGKIN’S LYMPHOMA

* FDA - GRANTED APPROVAL OF TRUXIMA TO CELLTRION AS FIRST BIOSIMILAR TO RITUXAN; RITUXAN IS MANUFACTURED BY GENENTECH.

* FDA - LABELING FOR TRUXIMA CONTAINS A BOXED WARNING. Source text: (bit.ly/2raPni4) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below